Complete pathological response to olaparib and bevacizumab in advanced cervical cancer following chemoradiation in a BRCA1 mutation carrier: a case report

Journal of Medical Case Reports

Géraldine Perkins¹  Rosa Montero-Macias²  Vincent Balay³  Huyen-Thu Nguyen-Xuan³  Meriem Koual⁴  Anne-Sophie Bats⁵  Marie Aude Le Frére-Belda⁶  Hélène Blons Hélène⁷  Simon Garinet⁷  Céline Crespel⁸  Marie Florin⁹  Catherine Durdux^1,10  Hélène Péré^1,11 

[1] Centre Universitaire des Saints-Pères, INSERM UMR-S 1147, Université de Paris, Paris, France;Department of Biology, European Georges-Pompidou Hospital, APHP. Centre, Paris, France;Department of Gynaecologic and Breast Oncological Surgery, European Georges-Pompidou Hospital, APHP. Centre, 20, rue Leblanc, 75908, Paris Cedex 15, France;Department of Gynaecologic and Breast Oncological Surgery, European Georges-Pompidou Hospital, APHP. Centre, 20, rue Leblanc, 75908, Paris Cedex 15, France;Faculty of Medicine, Paris University, Paris, France;Department of Gynaecologic and Breast Oncological Surgery, European Georges-Pompidou Hospital, APHP. Centre, 20, rue Leblanc, 75908, Paris Cedex 15, France;Faculty of Medicine, Paris University, Paris, France;Centre Universitaire des Saints-Pères, INSERM UMR-S 1124, Université de Paris, Paris, France;Department of Gynaecologic and Breast Oncological Surgery, European Georges-Pompidou Hospital, APHP. Centre, 20, rue Leblanc, 75908, Paris Cedex 15, France;Faculty of Medicine, Paris University, Paris, France;Centre Universitaire des Saints-Pères, INSERM UMR-S 1147, Université de Paris, Paris, France;Department of Pathology, European Georges-Pompidou Hospital, APHP. Centre, Paris, France;Faculty of Medicine, Paris University, Paris, France;Department of Biochemistry, European Georges-Pompidou Hospital, APHP. Centre, Paris, France;Centre Universitaire des Saints-Pères, INSERM UMR-S 1147, Université de Paris, Paris, France;Faculty of Medicine, Paris University, Paris, France;Department of Medical Oncology, European Georges-Pompidou Hospital, APHP. Centre, Paris, France;Faculty of Medicine, Paris University, Paris, France;Department of Radiology, European Georges-Pompidou Hospital, APHP. Centre, Paris, France;Faculty of Medicine, Paris University, Paris, France;Department of Radiotherapy, European Georges-Pompidou Hospital, APHP. Centre, Paris, France;Faculty of Medicine, Paris University, Paris, France;Department of Virology, European Georges-Pompidou Hospital, APHP. Centre, Paris, France;INSERM 970, Paris Centre de Recherche Cardiovasculaire (PARCC), European Georges-Pompidou Hospital, APHP. Centre, Paris, France;

关键词: Advanced cervical cancer;    BRCA1;    PARP inhibitor;    Olaparib;    Precision oncology;   

DOI  :  10.1186/s13256-021-02767-9

来源: Springer

【 摘 要 】

BackgroundHomologous recombination deficiency is a marker of response to poly(ADP-ribose) polymerase inhibitors in different cancer types including ovary, prostate, and pancreatic cancer. To date, no report about poly(ADP-ribose) polymerase inhibitors has been published on cervical cancer.Case presentationHere we present the case of a patient with cervical cancer treated in this setting. A 49-year-old woman diagnosed with International Federation of Obstetricians and Gynecologists stage 2018 IIIC2 locally advanced undifferentiated cervical cancer received first-line chemoradiotherapy followed by carboplatin, paclitaxel, and bevacizumab with partial response. Because of a family history of cancers, the patient was tested and found positive for a pathogenic BRCA1 germline and somatic mutation, which motivated bevacizumab plus olaparib maintenance treatment. A simple hysterectomy was performed after 2 years stable disease; pathological report showed complete pathological response, and 12 months follow-up showed no recurrence.ConclusionPoly(ADP-ribose) polymerase inhibitors could be an alternative maintenance treatment for patients with persistent advanced cervical cancer previously treated with platinum, especially when familial history of cancers is reported. Clinical trials using poly(ADP-ribose) polymerase inhibitors for advanced cervical cancer are warranted.

【 授权许可】

CC BY